UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

UroGen (Nasdaq: URGN) announced inducement restricted stock unit grants to 11 new employees on March 6, 2026. Up to 51,200 ordinary shares may be issued upon vesting. RSUs vest equally over three years (one-third annually) and are governed by UroGen's 2019 Inducement Plan.

The grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4) to support commercialization of JELMYTO and ZUSDUR and continued pipeline development.

News Market Reaction – URGN

-2.69%

2 alerts

-2.69% Session close to close

+8.3% Peak Tracked

$954.66M Market Cap

2.94K Volume

In the Mar 9 session, URGN declined 2.69%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement RSU grants for 11 new employees, covering up to 51,200 shares v...

Analysis

This announcement details inducement RSU grants for 11 new employees, covering up to 51,200 shares vesting over three years, aimed at supporting commercialization of JELMYTO and ZUSDUR and advancing the pipeline. It follows recent earnings, debt refinancing, and positive Phase 3 ENVISION data. Investors may monitor how ongoing equity-based compensation, insider Form 4 activity, and future clinical or commercial updates interact with this expanding talent base.

Key Figures

Inducement RSUs recipients: 11 new employees RSUs underlying shares: Up to 51,200 ordinary shares Vesting period: 3 years +1 more

4 metrics

Inducement RSUs recipients 11 new employees Equity awards under Nasdaq Listing Rule 5635(c)(4)

RSUs underlying shares Up to 51,200 ordinary shares Shares issuable upon RSU vesting and settlement

Vesting period 3 years RSUs vest in equal annual installments

Annual vesting fraction One-third per year Each anniversary of the vesting date, subject to continued service

Historical Context

5 past events · Latest: Mar 02 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 02	Earnings results	Negative	-12.3%	2025 results with net loss of $153.5M and updated revenue details.
Mar 02	Debt refinancing	Positive	-12.3%	Amended term loan with Pharmakon up to $250M at fixed 8.25% rate.
Feb 27	Clinical data update	Positive	+2.5%	ENVISION Phase 3 post‑hoc analyses showing durable ZUSDURI complete responses.
Feb 24	Conference participation	Neutral	-0.4%	Announcement of TD Cowen conference presentation and investor meetings.
Feb 23	Earnings date notice	Neutral	-0.7%	Scheduling of Q4 and full‑year 2025 results call and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows positive clinical data aligning with gains, while earnings and financing news often coincided with notable share price weakness.

Recent Company History

Over the last weeks, URGN reported multiple milestones. On Feb 27, positive Phase 3 ENVISION data for ZUSDURI with high complete response rates saw a 2.46% gain. In contrast, the Mar 2 earnings release with $109.8M 2025 revenue and the concurrent Pharmakon term loan refinancing to up to $250M both preceded a 12.35% drop. Conference participation and earnings-date notices in late February saw only small moves. Today’s inducement RSUs fit into a broader pattern of equity-based compensation activity shown in recent Form 4 filings.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4), intravesical, pyelocalyceal

4 terms

restricted stock units financial

"announced the grants of inducement restricted stock units (“RSUs”) to 11 new employees"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

intravesical medical

"ZUSDUR™ (mitomycin) for intravesical solution, UroGen’s only approved products"

Intravesical describes a medical treatment or procedure where a drug or therapy is placed directly into the bladder through a catheter rather than taken by mouth or injected into the bloodstream. For investors, it signals a focused delivery method that can increase local effectiveness and reduce whole‑body side effects, often affecting a product’s clinical value, patient convenience, regulatory path, and market niche — like watering a plant at its roots instead of spraying its leaves.

pyelocalyceal medical

"JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDUR™ (mitomycin) for intravesical solution"

Pyelocalyceal describes the parts of the kidney that collect and channel urine — the renal pelvis (a central funnel) and the calyces (small cups that feed into it). For investors, it matters when products, tests, or diseases target this area because clinical outcomes, regulatory approvals, and market demand for treatments or diagnostic tools can hinge on conditions like obstruction, infection, or tumors in these structures. Think of it as the plumbing junction inside a kidney where blockages or damage can drive medical and commercial activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 11 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO^® (mitomycin) for pyelocalyceal solution and ZUSDUR™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.

Up to 51,200 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit www.urogen.com or follow us on X, @UroGenPharma.

JELMYTO^®, RTGel^®, ZUSDURI™ and UroGen^® are registered trademarks of UroGen Pharma Ltd.

INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 Ext. 1093

MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3566 Ext. 1083

FAQ

What inducement grants did UroGen (URGN) announce on March 6, 2026?

UroGen granted restricted stock units to 11 new employees as inducements to join the company. According to UroGen, up to 51,200 ordinary shares are issuable upon RSU vesting under the company's 2019 Inducement Plan.

How do the UroGen (URGN) RSUs vest and when do shares become issuable?

The RSUs vest equally over three years with one-third vesting each anniversary of the vesting date. According to UroGen, shares become issuable upon vesting and settlement, subject to continued employee service and plan terms.

Why did UroGen (URGN) issue inducement RSUs under Nasdaq Listing Rule 5635(c)(4)?

UroGen issued RSUs as inducement awards to recruit key hires supporting commercialization and pipeline work. According to UroGen, the grants were material inducements tied to new employees' entry into employment in line with Nasdaq rules.

Which UroGen products will the newly hired employees support after the RSU grants?

The new employees will support commercialization of JELMYTO (mitomycin) and ZUSDUR (mitomycin) and ongoing pipeline development. According to UroGen, both JELMYTO and ZUSDUR are the company's only approved products currently.

Do the UroGen (URGN) inducement RSUs create immediate dilution for shareholders?

The RSUs allow issuance of up to 51,200 shares upon vesting, which could cause dilution when settled. According to UroGen, issuance is subject to vesting and plan terms, but the filing does not state the percentage dilution relative to outstanding shares.